



**Ninth
International Vein Congress®
Endovascular Venous Surgery**

DAILY NEWS

Friday, May 13, 2011

IVC 2011: Live Case Series

Every year, the live cases present a unique learning opportunity for IVC attendees. We will broadcast live cases from Miami Vein Center into the Sparkle Ballroom of the Fontainebleau Hotel. The operators will interact with a panel of experts to hash out the salient issues germane to each case. Both the video image and the ultrasound image are viewable on the big screen so that the audience gets the same experience as if standing in the operating room.

We try to adjust the focus from year-to-year so that new learning opportunities are presented for our returning guests. Last we demonstrated thermal and pharmacomechanical ablation of the great saphenous vein, ambulatory phlebectomy and ohmic thermolysis of spider telangiectasia. In 2009, we presented routine great saphenous vein ablation using different laser fiber tips and the endovenous treatment of an aneurysmal vein of the popliteal fossa. In 2008, we demonstrated anterior accessory saphenous vein ablation and recanalization/treatment of a previously thrombosed great saphenous vein. In 2007, we devoted extra time to the small saphenous vein, and in 2006 we demonstrated laser-assist-

ed distal vein stripping. Each patient this year presents with differing levels of complexity. Access, device placement and thermal energy delivery will be shown and discussed in detail. Pharmacomechanical great saphenous ablation will be demonstrated. Dr. Ed Mackay will demonstrate his approach to sclerotherapy of spi-



IVC Course Director Dr. Jose Almeida welcomes attendees on Thursday morning.

der telangiectasias using carbon dioxide-based foam. Ambulatory phlebectomy with a new disposable hook will be performed. We hope this will be a valuable learning experience for you.

We encourage audience participation by asking questions using the microphones situated in the Sparkle Ballroom.

Jose I. Almeida, M.D., FACS,
RPVI, RVT
IVC Course Director



Dr. John Koziarski packs 'em in during his talk about Corneal Infarct Following Foam Sclerotherapy during the mini-symposium featuring unusual venous cases.

IVC Gets Deep in More Ways than One

Practical, day-to-day management" and "evidence-based medicine" are the buzz phrases at IVC 2011. Course Director Jose I. Almeida, M.D., wants attendees to examine where their practices are headed, as well as how the field is changing.

"IVC's role is on the more practical side of running a practice," Dr. Almeida said. "We encourage you to take business into your own hands. Take control of your practice and see it as a business."

Attendees of past IVC meetings will be familiar with Dr. Almeida's personal story and how he took the leap to a vein-focused practice in 2002. He encourages attendees to look at the current direction of their practices, and decide if they need to

make some minor adjustments or a major overhaul.

Recognizing some shifts in reimbursement and anticipating further adjustments in healthcare disbursements down the road, Dr. Almeida this year has introduced presentations on deep venous disease and related endovascular procedures, which he recently began performing again. "I took a break for 10 years, now I want to get back into a little heavier stuff," he said. Some doctors will want to consider adding such procedures to their repertoire for financial reasons.

The concept of evidence-based medicine plays heavily into how the venous arena will continue to

Continued on page 3



Mahendran Ravichandran, Cook Medical representative, left, looks on as Trease Smock, N.P., and Drs. Jose Arias and Hector Lozano look at IVC filters during the afternoon break in the Exhibit Hall.

Friday at IVC

- Exhibits Open 7:00 a.m. – 5:00 p.m.
- General Session Continues 8:00 a.m.
- Industry Educational Session 12:00 – 1:00 p.m.
 - DVT Treatment and DVT Practice Building in 2011
Presented by Covidien
Location: Splash 9-11
- Optional Mini-symposia (see page 4) 4:15 p.m.
 - Mini-symposium 1: Sclerotherapy Symposium
(Location: Sparkle East)
 - Mini-symposium 2: Office Managers Symposium
Venous Surgeon (Location: Splash 9-11)

Nonthermal Ablation for the Treatment of Varicose Veins

The evolving minimally invasive methods for saphenous vein ablation

Reprinted with permission from the April 2011 issue of *Endovascular Today* magazine and available online at www.bmctoday.net/evtoday.

By Jose I. Almeida, M.D., FACS, RPVI, RVT

Thermal ablation for closure of an incompetent saphenous vein came on the scene just over 10 years ago; in the United States, it has virtually replaced traditional surgical saphenectomy (high ligation and stripping). Thermal ablation—either in the form of radiofrequency or laser electromagnetic energy—exemplifies the principles of the endovascular revolution. The minimally invasive solutions to vascular disease using image guidance offer a short hospital stay, quick recovery, durability, improved quality of life, minimal scarring, and an overall high-tech vibe. Since the advent of endovascular technology, most American patients now enjoy catheter-based solutions to their vascular problems on both the venous and arterial sides.

Endovenous thermal ablation of saphenous vein trunks has proven safe and durable. Currently, there are many devices available to physicians who are interested in treating patients with venous disease. All of the current devices boast excellent closure rates, and the differences lie mostly in postprocedure recovery.¹ All procedures require the use of perivenous tumescent anesthesia to mitigate the side effects of vein heating. There has been an interest in developing technology that eliminates the percutaneous placement of perivenous tumescent anesthesia, thus avoiding multiple noxious needle punctures.

Sclerotherapy, which does not require tumescent anesthesia for the treatment of varicose veins, has been available for decades. However, saphenous trunk closure with a variety of sclerosants has proven unreliable, with numerous publications showing high recanalization rates. To potentiate vein closure, sclerosants have been used as gaseous foams. Foam sclerotherapy has had a difficult time garnering approval from the US Food and Drug Administration because it has been shown to embolize systemically into the venous circulation and, rarely, into the arterial circulation via patent foramen ovale.

SAPHENOUS VEIN CLOSURE WITH CYANOACRYLATE ADHESIVE

Cyanoacrylate (CA) adhesives, commonly referred to as “super glue,” have gained momentum in recent years for intravascular use in

treating conditions such as arteriovenous malformations and pelvic congestion syndrome. When used intravascularly, CA triggers an acute inflammatory reaction in the vessel wall via a polymerization reaction. An inherent risk of an overdiluted CA compound (a polymerization rate that is too slow) is migration of the CA into unwanted areas because of low viscosity. Conversely, a polymerization rate that is too rapid may induce unwanted adhesion of the delivery catheter to the vessel because the compound cures too quickly. A new CA by Sapheon, Inc. with a



Figure 1. Sapheon closure system (Sapheon, Inc., Santa Rosa, CA).

proprietary blend of additives to affect polymerization is in the process of clinical testing. One advantage of a CA adhesive saphenous closure system is that the capital investment required to treat the saphenous vein is markedly reduced because a generator—such as those used for radiofrequency or laser ablation—is no longer required.

Animal Models

Care of the live animals complied with the National Institutes of Health guidelines for laboratory animals, and they were housed with care in accordance with United States Department of Agriculture regulations. Superficial epigastric veins from different animal models were used because of their similarity to the human great saphenous vein. Access was obtained using a standard micropuncture kit, and a 5-F sheath was advanced 2 cm caudad to the junction with the abdominus rectus veins. A dispenser gun attached to a catheter was used to inject 0.16 mL of CA, while compression was applied to occlude the venous junction (Figure 1). After delivery, the catheter was pulled back 3 cm, and manual venous compression was employed for 30 seconds over the CA delivery site. Animals were euthanized and examined either immediately, at 30 days, or at 60 days postimplantation.

The most exciting finding from the animal work was the fibrosis seen at 60 days postimplantation. The vein walls were segmentally thickened by fibrous tissue, and the lumen was filled with coalescing, arborizing bands of macrophages and spindle cells. The changes observed in the treated veins are consistent with chronic foreign body-type inflammatory response. Others have observed fibrosis at 2 to 3 months postimplantation using other CA formulations.²

First-in-Man

The protocol for this procedure was approved and performed in accordance with the Dominican National Council on Bioethics in Health (CONABIOS). Eight consecutive patients with incompetent great saphenous veins and signs or symptoms of chronic venous disease underwent saphenous vein closure with CA adhesive. The mean treatment time was 17 minutes, the mean treatment length was 31 cm, and the mean CA injected volume was 1.58 mL. All veins were closed at 1 month. Serious adverse events were nil. We concluded from this small pilot study that CA adhesive as an alternative treatment for the incompetent saphenous vein was feasible. A more robust study began in March 2011.

ADDRESSING THE VARICOSITIES

With respect to working with a saphenous vein closure device, which does not require tumescent anesthesia, the question becomes, “What is the compelling reason for using this device when the patient will need tumescent anesthesia regardless for phlebectomy of the varicosities?” There has been great debate (and sparse data) addressing the timing for treatment of the varicosities after saphenous ablation. Some operators prefer to deal with the varicosities at the same time as saphenous trunk ablation, while others prefer to stage the two procedures at different time intervals. The alternative, sclerotherapy treatment of the varicosities, is vexed with staining problems and a high recurrence rate.

PHLEBECTOMY

Tumescent anesthesia provides a safe, easy-to-administer technique for use with a phlebectomy procedure. The anesthetic preparation is administered subdermally under pressure. The tumescent fluid hydrodissects the subcutaneous fat from the venous tissue and also offers a bacteriostatic effect. Phlebectomy surgery requires a scalpel to make an incision, a hook to exteriorize the vein, and a hemostat for vein removal under traction.

The most popular instruments for creating phlebectomy incisions are No. 11 scalpel blades or 18-gauge needles. Incision length should correspond to vein size, but is usually in the range of 1 to 3 mm. Hooking the target vein through the small incision is the next step. There are multiple instruments available for hooking the vein, which are usually known by the inventor’s name. These instruments are made of nondisposable stainless steel and require autoclaving.

Disposable Vein Hook

The Disposable Vein Hook consists of a plastic handle with a blade and a retractable safety guard on one end and a hook on the opposite end, allowing physicians to quickly perform a phlebectomy procedure by making

the incision with the blade end and then turning the device around and using the hook end to remove the varicosity (Figure 2).

The Disposable Vein Hook is intended for singlepatient use for the treatment of superficial varicose veins associated with superficial reflux and incompetence of the great saphenous vein in the lower extremities. This procedure can be performed in conjunction with saphenous ablation or as a stand-alone procedure. The sterile, single-use Disposable Vein Hook is offered along with the Disposable Hemostat Pack (Vascular Solutions, Inc.), thereby eliminating the need and expense of an autoclave system.



Figure 2. Disposable Vein Hook (Vascular Solutions, Inc., Minneapolis, MN; developed by AM Phleb Device LLC, Miami, FL).

CONCLUSION

As nonthermal technology for saphenous vein ablation develops, we are seeing a potential trend that minimizes capital outlay for vein center start-up and improves the patient experience. Because the devices are disposable, one-time-use products, autoclaves and infectious disease policy and procedure protocols may no longer be necessary. One could argue further, that staging the saphenous closure followed by phlebectomy at a later stage may optimize the patient experience. Early data with CA saphenous closure demonstrates an innocuous postoperative recovery; therefore, if one allows 6 weeks for varicose vein shrinkage, the subsequent phlebectomy would be minimized, requiring only a disposable kit and a little local anesthetic. The minimally invasive revolution continues to evolve for the better.

Jose I. Almeida, MD, FACS, RPVI, RVT, is Director of the Miami Vein Center, Voluntary Associate Professor of Surgery at the University of Miami-Jackson Memorial Hospital. He has disclosed that he receives grant/research funding from Sapheon, Inc., and is a managing partner of AM Phleb Device LLC. Dr. Almeida may be reached at dralmeida@mac.com.

1. Almeida JI, Kaufman J, Göckeritz O, et al. Radiofrequency endovenous ClosureFAST versus laser ablation for the treatment of great saphenous reflux: a multicenter, single-blinded, randomized study (RECOVERY study). *J Vasc Interv Radiol*. 2009;20:752-759.

2. Wang YM, Cheng LF, Li N. Histopathological study of vascular changes after intra-arterial and intravenous injection of N-butyl-2-cyanoacrylate. *Chin J Dig Dis*. 2006;7:175-179.